NervGen is restoring life's potential by creating innovative solutions for the treatment of nerve damage.
NervGen’s core technology targets protein tyrosine phosphatase sigma (PTPσ), a neural receptor that impedes nerve regeneration. Inhibition of the PTPσ receptor has been shown to promote regeneration of damaged nerves and improvement of nerve function in animal models for various medical conditions. A series of receptor antagonists have been identified including a lead candidate ready for clinical development. NervGen plans to advance the lead candidate into the clinic initially for the treatment of spinal cord injury while exploiting the technology to identify additional therapeutic candidates for other related medical conditions.